Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 30;10(8):e037305.
doi: 10.1136/bmjopen-2020-037305.

Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)

Susanna J Lake  1   2 , Sophie L Phelan  3 , Daniel Engelman  1   2 , Oliver Sokana  4 , Titus Nasi  4 , Dickson Boara  4 , Christina Gorae  4 , Tibor Schuster  5 , Anneke C Grobler  6 , Millicent H Osti  1 , Ross Andrews  7 , Michael Marks  8   9 , Margot J Whitfeld  10 , Lucia Romani  3 , John Kaldor  3 , Andrew Steer  11   2
Affiliations

Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)

Susanna J Lake et al. BMJ Open. .

Abstract

Introduction: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-wide ivermectin-based mass drug administration (MDA) is an effective control strategy for scabies in island settings, with a single round of MDA reducing population prevalence by around 90%. However, current two-dose regimens present a number of barriers to programmatic MDA implementation. We designed the Regimens of Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose MDA may be as effective as two-dose MDA in controlling scabies in high-prevalence settings.

Methods and analysis: RISE is a cluster-randomised non-inferiority trial. The study will be conducted in 20 isolated villages in Western Province of Solomon Islands where population prevalence of scabies is approximately 20%. Villages will be randomly allocated to receive either one dose or two doses of ivermectin-based MDA in a 1:1 ratio. The primary objective of the study is to determine if ivermectin-based MDA with one dose is as effective as MDA with two doses in reducing the prevalence of scabies after 12 months. Secondary objectives include the effect of ivermectin-based MDA on impetigo prevalence after 12 and 24 months, the prevalence of scabies at 24 months after the intervention, the impact on presentation to health facilities with scabies and impetigo, and the safety of one-dose and two-dose MDA.

Ethics and dissemination: This trial has been approved by the ethics review committees of the Solomon Islands and the Royal Children's Hospital, Australia. Results will be disseminated in peer-reviewed publications and in meetings with the Solomon Islands Ministry of Health and Medical Services and participating communities.

Trial registration details: Australian New Zealand Clinical Trials Registry: ACTRN12618001086257. Date registered: 28 June 2018.

Keywords: dermatology; infectious diseases; international health services; tropical medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study location in Solomon Islands.
Figure 2
Figure 2
Study location in Western Province, Solomon Islands.
Figure 3
Figure 3
Study flow diagram. approx., approximately; MDA, mass drug administration
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vos T, Abajobir AA, Abate KH, et al. . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet 2017;390:1211–59. 10.1016/S0140-6736(17)32154-2 - DOI - PMC - PubMed
    1. Karimkhani C, Colombara DV, Drucker AM, et al. . The global burden of scabies: a cross-sectional analysis from the global burden of disease study 2015. Lancet Infect Dis 2017;17:1247–54. 10.1016/S1473-3099(17)30483-8 - DOI - PMC - PubMed
    1. Hardy M, Engelman D, Steer A. Scabies: a clinical update. Aust Fam Physician 2017;46:264–8. - PubMed
    1. Mellanby K. Transmission of scabies. Br Med J 1941;2:405–6. 10.1136/bmj.2.4211.405 - DOI - PMC - PubMed
    1. Romani L, Steer AC, Whitfeld MJ, et al. . Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis 2015;15:960–7. 10.1016/S1473-3099(15)00132-2 - DOI - PubMed

Publication types